<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy : CII</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998679</article-id><article-id pub-id-type="pmc">PMC11861465</article-id>
<article-id pub-id-type="publisher-id">3966</article-id><article-id pub-id-type="doi">10.1007/s00262-025-03966-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ramos-Guerra</surname><given-names>Ana D.</given-names></name><address><email>ana.ramos.guerra@upm.es</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Farina</surname><given-names>Benito</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rubio P&#x000e9;rez</surname><given-names>Jaime</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Vilalta-Lacarra</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Zugazagoitia</surname><given-names>Jon</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Peces-Barba</surname><given-names>Germ&#x000e1;n</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Seijo</surname><given-names>Luis M.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Paz-Ares</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Gil-Bazo</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>D&#x000f3;mine G&#x000f3;mez</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ledesma-Carbayo</surname><given-names>Mar&#x000ed;a J.</given-names></name><address><email>mj.ledesma@upm.es</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03n6nwv02</institution-id><institution-id institution-id-type="GRID">grid.5690.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 2978</institution-id><institution>Biomedical Image Technologies, Escuela T&#x000e9;cnica Superior de Ingenieros de Telecomunicaci&#x000f3;n, </institution><institution>Universidad Polit&#x000e9;cnica de Madrid, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ca2c886</institution-id><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Bioingenier&#x000ed;a, Biomateriales y Nanomedicina, </institution><institution>Instituto de Salud Carlos III, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/049nvyb15</institution-id><institution-id institution-id-type="GRID">grid.419651.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9538 1950</institution-id><institution>Hospital Universitario Fundaci&#x000f3;n Jim&#x000e9;nez D&#x000ed;az, IIS-FJD, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03phm3r45</institution-id><institution-id institution-id-type="GRID">grid.411730.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2191 685X</institution-id><institution>Department of Medical Oncology, </institution><institution>Cl&#x000ed;nica Universidad de Navarra, </institution></institution-wrap>Pamplona, Spain </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ca2c886</institution-id><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de C&#x000e1;ncer, </institution><institution>Instituto de Salud Carlos III, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00qyh5r35</institution-id><institution-id institution-id-type="GRID">grid.144756.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1945 5329</institution-id><institution>Hospital Universitario 12 de Octubre, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ca2c886</institution-id><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Enfermedades Respiratorias, </institution><institution>Instituto de Salud Carlos III, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff9"><label>9</label>Department of Oncology, Hospital Vithas Vitoria, Vitoria, Spain </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03d7a9c68</institution-id><institution-id institution-id-type="GRID">grid.440831.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1804 6963</institution-id><institution>School of Medicine, </institution><institution>Universidad Cat&#x000f3;lica de Valencia, </institution></institution-wrap>Valencia, Spain </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>74</volume><issue>4</issue><elocation-id>120</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>1</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The identification of non-small cell lung cancer (NSCLC) patients who will benefit from immunotherapy remains a clinical challenge. Monitoring real-world data (RWD) in the first cycles of therapy may provide a more accurate representation of response patterns in a real-world setting. We propose a multivariate Bayesian joint model using generalized linear mixed effects, trained and validated on RWD from 424 advanced NSCLC patients retrospectively collected from three clinical centers. Center1 was used as training (<inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N=212$$\end{document}</tex-math><mml:math id="M2"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>212</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq1.gif"/></alternatives></inline-formula>), while Center2 and Center3 were used as independent testing sets (<inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N=137$$\end{document}</tex-math><mml:math id="M4"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>137</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq2.gif"/></alternatives></inline-formula> and <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N=75$$\end{document}</tex-math><mml:math id="M6"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>75</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq3.gif"/></alternatives></inline-formula>, respectively). Peripheral blood data (PBD) were collected at baseline and at three follow-up time points, alongside demographic and epidemiologic features. Six models were trained to predict progression-free survival at 6 months, PFS(6), using different number of longitudinal samples (baseline, two, or four time points) of the neutrophil-to-lymphocyte ratio (NLR) or a multivariate feature selection. Long-term predictions at 12 and 24 months were also evaluated. Prediction accuracy was measured using the area under the receiver operating characteristic curve (AUC). The proposed model significantly improved prediction performance, achieving AUCs of 0.870, 0.804 and 0.827 at 6, 12 and 24 months for Center2, and 0.824, 0.822 and 0.667 for Center3. There was also a significant difference in PFS and overall survival (OS) between predicted response groups, defined by a 6-month PFS cutoff (log-rank test <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.001$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq4.gif"/></alternatives></inline-formula>). Our study suggests that the integration of multiple biomarkers and monitored PBD in an RWD-based Bayesian joint model framework significantly improves immunotherapy response prediction in advanced NSCLC compared to conventional approaches involving biomarker data at baseline only.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00262-025-03966-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Non-small-cell lung cancer</kwd><kwd>Peripheral blood biomarker</kwd><kwd>Immunotherapy</kwd><kwd>Longitudinal analysis</kwd><kwd>Prognostic marker</kwd><kwd>Real-world data</kwd></kwd-group><funding-group><award-group><funding-source><institution>Agencia Estatal de Investigaci&#x000f3;n</institution></funding-source><award-id>PDC2022-133865-I00</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Fundaci&#x000f3;n BBVA</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Instituto de Salud Carlos III</institution></funding-source><award-id>PMP21/00107</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>European Commission</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Universidad Polit&#x000e9;cnica de Madrid</institution></funding-source></award-group><open-access><p>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Lung cancer is the leading cause of cancer death worldwide and exhibits a 5-year survival rate of 19% [<xref ref-type="bibr" rid="CR1">1</xref>]. In case of distant metastasis, which accounts for 57% of all lung cancer patients, the survival rate drops to 5%. The most prevalent diagnosis is non-small cell lung cancer (NSCLC), which represents 85% of all lung cancer cases [<xref ref-type="bibr" rid="CR1">1</xref>]. In addition to more conventional treatments, such as chemotherapy and radiotherapy, immune checkpoint inhibitors have widened the scope of cancer treatments, significantly improving patient prognosis by enhancing the immune response and reversing the tumor&#x02019;s immune-blocking mechanisms [<xref ref-type="bibr" rid="CR2">2</xref>]. Despite pathways underlying immunotherapy response have been thoroughly explored, they do not always provide the proper clinical response even in eligible subjects [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Studies indicate that a significant proportion of those who initially respond to first-line therapy eventually experience disease progression, along with the potential risk of severe and life-threatening side effects [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par3">Predicting the response to immunotherapy would facilitate the development of optimal treatment strategies, enable the focus of clinical trials on specific patient groups, enhance the effectiveness and personalization of patient care, minimize the probability of unnecessary side effects, and reduce healthcare costs [<xref ref-type="bibr" rid="CR6">6</xref>]. A growing number of decision support tools have been proposed that make use of a wide range of data sources, including clinical, radiological, histopathological, and genomic information. These tools often exploit the latest advances in statistical, machine learning, and deep learning techniques [<xref ref-type="bibr" rid="CR7">7</xref>]. However, these studies typically demand large cohorts and interpreting results presents a significant challenge. Furthermore, studies often exclude cases with loss to follow-up, which introduces bias, restricts the pool of available patients and increases the complexity of algorithm training [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par4">The utilization of data collected from routine clinical practice, also known as real-world data (RWD), may offer a more comprehensive understanding of cancer survival and progression in a real-world setting [<xref ref-type="bibr" rid="CR9">9</xref>]. Among the well-established predictive biomarkers derived from blood samples in cancer, the neutrophil-to-lymphocyte ratio (NLR) is regarded as one of the most straightforward standard indicators of systemic inflammation [<xref ref-type="bibr" rid="CR10">10</xref>]. The predictive value of NLR has been demonstrated at both baseline and over time, although studied in a discrete, rather than longitudinal, manner [<xref ref-type="bibr" rid="CR11">11</xref>]. Other ratios and scores have been widely studied and are used to assess the general condition of the patient, cancer progression, nutritional status, and the immune and inflammatory tumor context. These include the monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), advanced lung cancer inflammation index (ALI) and prognostic nutritional index (PNI) [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par5">It has been observed that alterations in the tumor-associated immune landscape occur during therapy. Blood tests are typically performed before each immunotherapy cycle, making hemogram results easy to use as a monitoring method. Consequently, the use of pretreatment information as a sole predictor of patient progression may be inadequate, despite its frequent use in previous research [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par6">Joint modeling (JM) is a robust statistical approach that accounts for the dependence and association between longitudinal and time-to-event data. Rizopoulos enabled the incorporation of multiple longitudinal variables while ensuring realistic computation times and developed accessible software for JM implementation [<xref ref-type="bibr" rid="CR16">16</xref>]. The methodology has since been implemented in other software tools such as <italic>Stan, Monolix</italic>, and <italic>NONMEM</italic> [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par7">JMs offer several advantages over traditional time-series methods [<xref ref-type="bibr" rid="CR19">19</xref>], such as accounting for censored data and providing uncertainty quantification, an essential feature when dealing with limited, temporal, and incomplete clinical datasets. JMs also show a reduced bias in parameter estimation and an increased efficiency of statistical inference over other methods [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par8">In oncology, JM applications mainly focus on pharmacodynamics and lesion kinetics, as seen in recent research [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Very few studies have explored the relationship between longitudinal peripheral blood data beyond NLR and time-to-event data in cancers other than NSCLC [<xref ref-type="bibr" rid="CR23">23</xref>]. In this context, a survival Bayesian joint model, trained with RWD collected over time, may effectively capture immune changes that occur during the initial cycles of immunotherapy. Such changes may serve to either increase or decrease the risk of progression and death in patients with NSCLC. In this study, we evaluate the performance of the proposed model in comparison with a Cox proportional hazard approach that relies exclusively on baseline and first-cycle information. Furthermore, we assess the efficacy of a multivariate setting in contrast to an NLR univariate approach.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patient cohort</title><p id="Par9">We conducted a retrospective study of 514 advanced NSCLC patients from three clinical centers: Hospital Universitario Fundaci&#x000f3;n Jim&#x000e9;nez D&#x000ed;az (Center1, <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N=219$$\end{document}</tex-math><mml:math id="M10"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>219</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq5.gif"/></alternatives></inline-formula>), Cl&#x000ed;nica Universidad de Navarra (Center2, <inline-formula id="IEq6"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N=174$$\end{document}</tex-math><mml:math id="M12"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>174</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq6.gif"/></alternatives></inline-formula>), and Hospital Universitario 12 de Octubre (Center3, N=121). Patient inclusion criteria incorporated (a) confirmed stage III-IV NSCLC, excluding the neuroendocrine subtype due to its unique treatment response [<xref ref-type="bibr" rid="CR24">24</xref>]; (b) treatment consisting of immunotherapy as monotherapy or a combination of immune-based agents, or concurrently with conventional (e.g., chemotherapy, radiation therapy) or targeted therapies (TT); (c) availability of baseline peripheral blood data (PBD), clinical and epidemiological information.</p><p id="Par10">Given the inclusion criteria, the final cohorts comprised 424 patients with advanced NSCLC who received immunotherapy treatment in a variety of settings, covering routine clinical care, clinical trials, expanded access, and compassionate use programs (see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Treatment comprised programmed cell death protein 1 (PD-1)/PD-L1 inhibitors (pembrolizumab, atezolizumab, durvalumab, nivolumab and cemiplimab) and other immunotherapy drugs: anti-CTLA-4, anti-ICOS, anti-TIM-3, anti-FAP-IL-2v and anti-CSF1R. The age of the patients varied from 32 to 89 years, including 307 men (72%) and 117 women (28%).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of study cohorts. The final number of patients and the follow-up temporal range is provided for the Center1 training set and Center2 and Center3 independent testing sets. Patients who were excluded from the study belonged to the neuroendocrine subtype, NSCLC stage I-II and/or the control arm of an immunotherapy clinical trial. Additionally, patients without baseline hemogram data and/or loss to follow-up after initiating therapy were also not considered. This study analyzed models using (1) baseline data exclusively (BM), (2) the difference between data from the first and second immunotherapy cycle (DM) and (3) any available longitudinal data up to the fifth immunotherapy cycle (JM). Patients lacking second-cycle data were excluded from the DM analysis</p></caption><graphic xlink:href="262_2025_3966_Fig1_HTML" id="MO1"/></fig></p><p id="Par11">This retrospective study was approved by the institutional review boards of the three clinical centers involved and informed consent was collected accordingly.</p></sec><sec id="Sec4"><title>Data collection</title><p id="Par12">PBD was collected from electronical health records (EHRs), covering complete blood cell counts, lactate dehydrogenase (LDH) and albumin (ALB) levels. PBD also comprised multiple scores reported to be potentially predictive and/or prognostic biomarkers for NSCLC: NLR, MLR, PLR, ALI, SII and PNI. Data was collected at baseline and during three follow-up time points within the first 3 months of treatment, corresponding to immunotherapy cycles C1, C2, C3, and C5. The time between administration cycles varied between immunotherapy drugs due to differing regimens and discontinuation due to immune-related adverse effects (irAEs).</p><p id="Par13">Data on demographic profile, surgery, tumor characterization, antibiotic and steroid use, irAEs and other medical complications were also collected. irAEs considered were diarrhea, thyroiditis, pneumonitis, colitis, hepatitis, adrenal insufficiency, dermatitis, hypophisitis, and encephalitis. The variables used to model the progression to immunotherapy are shown in Table <xref rid="MOESM1" ref-type="media">S1</xref>.</p></sec><sec id="Sec5"><title>Response assessment</title><p id="Par14">Progression-free survival (PFS) was defined as the time from the first cycle of immunotherapy to clinical or radiological progression, leading to the end of treatment, death from any cancer-related cause, or last follow-up [<xref ref-type="bibr" rid="CR25">25</xref>]. RECIST response, categorized as complete response, partial response, stable disease, or progressive disease, along with overall response rate (ORR), was collected to describe the population. Overall survival (OS) was the time from treatment initiation to death from cancer-related cause or last follow-up. All models were trained to predict PFS at 6 months, PFS(6), ensuring a consistent comparison across models and facilitating model evaluation. Patients with a PFS greater than 6 months were considered responders [<xref ref-type="bibr" rid="CR26">26</xref>]. Inferences were made at 6, 12 and 24 months to evaluate the long-term predictive ability of models.</p></sec><sec id="Sec6"><title>Statistical analysis and model design</title><sec id="Sec7"><title>Data split</title><p id="Par15">Center1 (212 patients) was used as training, while the Center2 and Center3 were used as independent testing sets, with 137 and 75 patients, respectively. The training set was further divided into a tuning (70%) and a validation set (30%) for optimal model feature selection, ensuring a balanced representation of responders and non-responders. After tuning, the final model was trained on the entire Center1 dataset.</p></sec><sec id="Sec8"><title>Data preprocessing</title><p id="Par16">One-hot encoding was applied for categorical variables, and missing baseline data was imputed using mean and mode values from the training set. For Center3, variables not collected (ALB, surgical history and pack years) were imputed for all patients. The amount of imputation required per feature and clinical center is described in Table <xref rid="MOESM1" ref-type="media">S2</xref>. Since only two variables had &#x0003e;&#x000a0;20% of missing at random in the training set, we considered the inclusion of all collected variables for the imputation and further feature selection processes. Longitudinally, not all study variables were collected consistently for each immunotherapy cycle. For each patient, those time points for which a blood test was not performed were excluded. Missing values at a given time point for which hemogram was carried out but did not have complete information were imputed. The methodology used maintains the integrity of PBD evolution profiles by using a different imputation approach for each case [<xref ref-type="bibr" rid="CR27">27</xref>]: the rolling mean [<xref ref-type="bibr" rid="CR28">28</xref>], if previous and posterior time points were available; the last observation carried forward [<xref ref-type="bibr" rid="CR29">29</xref>], if only the previous time point was present; the next observation carried backward [<xref ref-type="bibr" rid="CR30">30</xref>], if the following recorded value was available; or the mean, if no information was collected.</p><p id="Par17">Continuous variables were normalized using min&#x02013;max normalization for a more stable optimization process, better balanced gradients, improved covariance estimation, and enhanced convergence in the joint model.</p></sec><sec id="Sec9"><title>Model design</title><p id="Par18">Two different models were trained: Cox proportional hazards model (CPH) and Bayesian joint model (JM) [<xref ref-type="bibr" rid="CR31">31</xref>]. For JM, a linear mixed-effects model was used as the longitudinal submodel, while a CPH model was used as the survival submodel to facilitate performance comparison with the BM and DM CPH models. In CPH the baseline hazard is left unspecified, providing flexibility and ensuring that the model is not constrained to a particular distribution of survival times. Schoenfeld residuals were analyzed to check if the proportional hazards assumption was met. CPH allowed to study the effect of each model variable on the risk of experiencing progression. JM also modeled the average longitudinal trajectory (slope), the baseline mean value associated to each monitored variable or intercept, and the error (<inline-formula id="IEq7"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sigma$$\end{document}</tex-math><mml:math id="M14"><mml:mi>&#x003c3;</mml:mi></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq7.gif"/></alternatives></inline-formula>). Given intercepts and slopes in the longitudinal submodel and HRs from the survival submodel, we can identify how temporal changes affect progression in relation to other model features.</p><p id="Par19">For JM models, the default setup in the R package <italic>JMbayes</italic> was used (version 0.8&#x02013;85). Model parameters were estimated by drawing Markov Chain Monte Carlo (MCMC) samples from the joint posterior distribution given the parameter prior distribution. Multivariate mixed effects were implemented in <italic>JAGS</italic> through <italic>rjags</italic> (version 4.10) and it was assumed that temporal information followed a Gaussian distribution. For priors, we followed the standard assumptions of the <italic>JMbayes</italic> framework. Specifically, independent univariate normal priors were assigned to the regression coefficients in both the longitudinal and survival submodels, as well as to the vector of association parameters. Variance parameters for normal longitudinal outcomes were modeled using inverse-gamma priors, while variance&#x02013;covariance matrices were assigned an inverse Wishart distribution. Parameter sampling was performed using random walk Metropolis, except for the precision parameter of the error terms, for which slice sampling was used. 10,000 iterations were performed and the burn-in period was set to 3000 iterations. For assessing algorithm convergence, we fitted four separate MCMC chains and computed the Gelman&#x02013;Rubin diagnostic <inline-formula id="IEq8"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hat{\hbox {R}}$$\end{document}</tex-math><mml:math id="M16"><mml:mover accent="true"><mml:mtext>R</mml:mtext><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq8.gif"/></alternatives></inline-formula>.</p></sec><sec id="Sec10"><title>Feature and model selection</title><p id="Par20">Wilcoxon Mann&#x02013;Whitney, Pearson <inline-formula id="IEq9"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\chi }^2$$\end{document}</tex-math><mml:math id="M18"><mml:msup><mml:mrow><mml:mi>&#x003c7;</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq9.gif"/></alternatives></inline-formula> and Fisher&#x02019;s exact tests were used to compare feature differences between clinical centers. Models differ in the subset of variables and use of monitored features. For multivariate models, a stepwise selection was used, based on the area under the time-dependent ROC curve (AUC) in the validation set. The null CPH AUC was used as reference. A multivariate selection (MV) was compared with using NLR. Three additional model variants were considered: baseline models (BM) using data from C1, delta models (DM) using the difference between data from C1 and C2 (i.e., <inline-formula id="IEq10"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta$$\end{document}</tex-math><mml:math id="M20"><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq10.gif"/></alternatives></inline-formula>variable), and longitudinal models (JM) incorporating data from C1, C2, C3, and C5.</p><p id="Par21">In summary, six models were compared: MV-BM, MV-DM, MV-JM, NLR-BM, NLR-DM and NLR-JM. The optimal threshold for categorizing patients as responders (PFS&#x0003e;6) and non-responders (PFS&#x0003c;6) was determined using maximally selected rank statistics via 4-fold cross-validation on the Center1 training set and the average value was applied to the testing sets.</p></sec><sec id="Sec11"><title>Model evaluation</title><p id="Par22">Hazard ratios (HR) were used to analyze the effect and importance of each model variable, where HR&#x0003c;1 indicated lower progression risk and HR&#x0003e;1 indicated higher risk. The HRs computed by the models correspond to a one-unit change in the normalized scale (<inline-formula id="IEq11"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {norm}}$$\end{document}</tex-math><mml:math id="M22"><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>norm</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq11.gif"/></alternatives></inline-formula>) for the normalized continuous variables. For interpretability purposes, we also present the HRs for a one-unit change in the variable&#x02019;s original scale, <inline-formula id="IEq12"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}$$\end{document}</tex-math><mml:math id="M24"><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq12.gif"/></alternatives></inline-formula> (see Tables <xref rid="MOESM1" ref-type="media">S4</xref>&#x02013;<xref rid="MOESM1" ref-type="media">S9</xref>). Parameter identifiability was not reached for variables with a relative standard error (RSE) exceeding 50%, based on the investigated data. The 10-fold cross-validation information criterion (10-fold IC) was used to assess the goodness of fit of the different models. Time-dependent AUC, sensitivity, and specificity values were used to analyze the discriminatory power at 6, 12 and 24 months [<xref ref-type="bibr" rid="CR32">32</xref>]. Youden index (J) identified the model with the best sensitivity&#x02013;specificity tradeoff. Standard deviations (SD) for all metrics were computed by bootstrapping with 1000 replications. Kaplan&#x02013;Meier method and log-rank test compared OS and PFS probabilities between predicted responder or non-responder groups, significant if p&#x0003c;0.05. Simulated survival curves were averaged from predicted individual curves. Model evaluation was conducted on the two testing sets to evaluate robustness. Additionally, we computed AUC considering the data from all centers.</p><p id="Par23">All data analysis and model generation was performed using R version 3.6.0.</p></sec></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>Population characteristics</title><p id="Par24">Significant differences were observed in the outcomes and the immunotherapy regimens assigned for each clinical center (Table <xref rid="Tab1" ref-type="table">1</xref>). First-line immunotherapy was the most common choice for Center1 (131, 62%), with pembrolizumab as the most used therapy (139, 66%), while fewer Center3 patients received first-line treatment (10, 13%) and pembrolizumab (12, 16%). A lower rate was also observed in Center2: 52 (38%) first-line and 54 (39%) pembrolizumab cases. The first-line treatment group exhibited significantly longer PFS and OS (PFS <inline-formula id="IEq13"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.001$$\end{document}</tex-math><mml:math id="M26"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq13.gif"/></alternatives></inline-formula>, OS <inline-formula id="IEq14"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.05$$\end{document}</tex-math><mml:math id="M28"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq14.gif"/></alternatives></inline-formula>) across the entire population. Monotherapy was the only treatment provided to all patients in H120 (75 patients, 100%), while it accounted for 56% of treatments in Center1 (118 patients) and 55% in Center2 (75 patients). No significant differences were observed when comparing monotherapy with combined immunotherapy protocols across the entire population. The distribution of PFS and OS was significantly independent according to the long-rank test for the Center1 and Center3 clinical centers (PFS <inline-formula id="IEq15"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.01$$\end{document}</tex-math><mml:math id="M30"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq15.gif"/></alternatives></inline-formula>, OS <inline-formula id="IEq16"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.001$$\end{document}</tex-math><mml:math id="M32"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq16.gif"/></alternatives></inline-formula>). PFS and OS curves of Center1, Center2 and Center3 clinical centers, line, and treatment option are shown in Fig. <xref rid="MOESM1" ref-type="media">S1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of patient outcomes and treatment information for individuals from Center1 (train set), and Center2 and Center3 (independent test sets). <italic>p</italic>-value of difference between Center1 and Center2 and Center3 was computed by the Wilcoxon Mann&#x02013;Whitney test for continuous features and Pearson <inline-formula id="IEq17"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\chi }^2$$\end{document}</tex-math><mml:math id="M34"><mml:msup><mml:mrow><mml:mi>&#x003c7;</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq17.gif"/></alternatives></inline-formula> or Fisher&#x02019;s exact test for categorical variables</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Center1</th><th align="left">Center2</th><th align="left"><italic>p</italic></th><th align="left">Center3</th><th align="left"><italic>p</italic></th></tr></thead><tbody><tr><td align="left"><italic>No. of patients, n(%)</italic></td><td align="left">212 (50)</td><td align="left">137 (32)</td><td align="left"/><td align="left">75 (18)</td><td align="left"/></tr><tr><td align="left"><italic>PFS, months</italic></td><td align="left"/><td align="left"/><td align="left">0.270</td><td align="left"/><td align="left">0.05</td></tr><tr><td align="left">Median</td><td align="left">5.60</td><td align="left">3.80</td><td align="left"/><td align="left">3.30</td><td align="left"/></tr><tr><td align="left">95% CI</td><td align="left">8.02<inline-formula id="IEq18"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M36"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq18.gif"/></alternatives></inline-formula>10.95</td><td align="left">8.48<inline-formula id="IEq19"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M38"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq19.gif"/></alternatives></inline-formula>13.40</td><td align="left"/><td align="left">4.98<inline-formula id="IEq20"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M40"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq20.gif"/></alternatives></inline-formula>9.10</td><td align="left"/></tr><tr><td align="left"><italic>Progression, n(%)</italic></td><td align="left">157 (74)</td><td align="left">116 (85)</td><td align="left">*</td><td align="left">68 (91)</td><td align="left">** <inline-formula id="IEq21"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M42"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq21.gif"/></alternatives></inline-formula></td></tr><tr><td align="left"><italic>Progression after 6 mo, n(%)</italic></td><td align="left">100 (47)</td><td align="left">58 (42)</td><td align="left">0.44</td><td align="left">28 (37)</td><td align="left">0.18</td></tr><tr><td align="left"><italic>ORR, n(%)</italic></td><td align="left">63 (30)</td><td align="left">27 (20)</td><td align="left">*</td><td align="left">13 (17)</td><td align="left">0.05</td></tr><tr><td align="left"><italic>RECIST response, n(%)</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Complete response</td><td align="left">13 (6)</td><td align="left">13 (9)</td><td align="left">0.24</td><td align="left">1 (1)</td><td align="left">0.18</td></tr><tr><td align="left">Partial response</td><td align="left">50 (24)</td><td align="left">14 (10)</td><td align="left">**<inline-formula id="IEq22"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M44"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq22.gif"/></alternatives></inline-formula></td><td align="left">12 (16)</td><td align="left">0.23</td></tr><tr><td align="left">Stable disease</td><td align="left">43 (20)</td><td align="left">6 (4)</td><td align="left">*** <inline-formula id="IEq23"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M46"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq23.gif"/></alternatives></inline-formula></td><td align="left">25 (33)</td><td align="left">*</td></tr><tr><td align="left">Progressive disease</td><td align="left">83 (39)</td><td align="left">66 (48)</td><td align="left">0.14</td><td align="left">37 (49)</td><td align="left">0.09</td></tr><tr><td align="left"><italic>OS, months</italic></td><td align="left"/><td align="left"/><td align="left">0.22</td><td align="left"/><td align="left">0.70</td></tr><tr><td align="left">Median</td><td align="left">10.00</td><td align="left">11.00</td><td align="left"/><td align="left">12.00</td><td align="left"/></tr><tr><td align="left">95% CI</td><td align="left">12.18<inline-formula id="IEq24"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M48"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq24.gif"/></alternatives></inline-formula>16.19</td><td align="left">15.60<inline-formula id="IEq25"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M50"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq25.gif"/></alternatives></inline-formula>22.48</td><td align="left"/><td align="left">10.41<inline-formula id="IEq26"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$-$$\end{document}</tex-math><mml:math id="M52"><mml:mo>-</mml:mo></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq26.gif"/></alternatives></inline-formula>14.96</td><td align="left"/></tr><tr><td align="left"><italic>Dead, n(%)</italic></td><td align="left">100 (47)</td><td align="left">96 (70)</td><td align="left">***</td><td align="left">62 (83)</td><td align="left">*** <inline-formula id="IEq27"><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M54"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq27.gif"/></alternatives></inline-formula></td></tr><tr><td align="left"><italic>Line, n(%)</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">1st</td><td align="left">131 (62)</td><td align="left">52 (38)</td><td align="left">*** <inline-formula id="IEq28"><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M56"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq28.gif"/></alternatives></inline-formula></td><td align="left">10 (13)</td><td align="left">*** <inline-formula id="IEq29"><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M58"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq29.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">2nd</td><td align="left">56 (26)</td><td align="left">48 (35)</td><td align="left">0.11</td><td align="left">50 (67)</td><td align="left">*** <inline-formula id="IEq30"><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M60"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq30.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">3rd or more</td><td align="left">25 (12)</td><td align="left">37 (27)</td><td align="left">*** <inline-formula id="IEq31"><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M62"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq31.gif"/></alternatives></inline-formula></td><td align="left">15 (20)</td><td align="left">0.12</td></tr><tr><td align="left"><italic>Treatment, n(%)</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Monotherapy</td><td align="left">118 (56)</td><td align="left">75 (55)</td><td align="left">0.95</td><td align="left">75 (100)</td><td align="left">***</td></tr><tr><td align="left">Combined IO</td><td align="left">12(6)</td><td align="left">27 (20)</td><td align="left">*** <inline-formula id="IEq32"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M64"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq32.gif"/></alternatives></inline-formula></td><td align="left">0 (0)</td><td align="left">0.08</td></tr><tr><td align="left">IO &#x00026; CT</td><td align="left">65 (31)</td><td align="left">24 (17)</td><td align="left">**</td><td align="left">0 (0)</td><td align="left">*** <inline-formula id="IEq33"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M66"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq33.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">IO &#x00026; RT</td><td align="left">12 (6)</td><td align="left">8 (6)</td><td align="left">1.00</td><td align="left">0 (0)</td><td align="left">0.08</td></tr><tr><td align="left">IO &#x00026; TT</td><td align="left">5 (2)</td><td align="left">3 (2)</td><td align="left">1.00</td><td align="left">0 (0)</td><td align="left">1.00</td></tr><tr><td align="left"><italic>Immune drug, n(%)</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Pembrolizumab</td><td align="left">139 (66)</td><td align="left">54 (39)</td><td align="left">*** <inline-formula id="IEq34"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M68"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq34.gif"/></alternatives></inline-formula></td><td align="left">12 (16)</td><td align="left">***</td></tr><tr><td align="left">Atezolizumab</td><td align="left">23 (11)</td><td align="left">33 (24)</td><td align="left">** <inline-formula id="IEq35"><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M70"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq35.gif"/></alternatives></inline-formula></td><td align="left">7 (23)</td><td align="left">*</td></tr><tr><td align="left">Nivolumab</td><td align="left">13 (6)</td><td align="left">46 (34)</td><td align="left">*** <inline-formula id="IEq36"><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M72"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq36.gif"/></alternatives></inline-formula></td><td align="left">28 (37)</td><td align="left">***</td></tr><tr><td align="left">Other</td><td align="left">37 (17)</td><td align="left">4 (3)</td><td align="left">*** <inline-formula id="IEq37"><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M74"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq37.gif"/></alternatives></inline-formula></td><td align="left">18 (24)</td><td align="left">0.29</td></tr><tr><td align="left"><italic>PDL-1, n(%)</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x0003c;&#x000a0;1%</td><td align="left">50 (24)</td><td align="left">28 (20)</td><td align="left">0.58</td><td align="left">62 (83)</td><td align="left">***</td></tr><tr><td align="left">1&#x02013;50%</td><td align="left">87 (41)</td><td align="left">81 (59)</td><td align="left">0.51</td><td align="left">6 (8)</td><td align="left">***</td></tr><tr><td align="left"><inline-formula id="IEq38"><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\ge$$\end{document}</tex-math><mml:math id="M76"><mml:mo>&#x02265;</mml:mo></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq38.gif"/></alternatives></inline-formula>&#x000a0;50%</td><td align="left">75 (35)</td><td align="left">28 (20)</td><td align="left">**</td><td align="left">7 (9)</td><td align="left">***</td></tr></tbody></table><table-wrap-foot><p><inline-formula id="IEq39"><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{*}$$\end{document}</tex-math><mml:math id="M78"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo></mml:mrow></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq39.gif"/></alternatives></inline-formula> p value&#x0003c;0.05, <inline-formula id="IEq40"><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{**}$$\end{document}</tex-math><mml:math id="M80"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo><mml:mrow/><mml:mo>&#x02217;</mml:mo></mml:mrow></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq40.gif"/></alternatives></inline-formula>
<italic>p</italic>-value &#x0003c; 0.01, <inline-formula id="IEq41"><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{***}$$\end{document}</tex-math><mml:math id="M82"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo><mml:mrow/><mml:mo>&#x02217;</mml:mo><mml:mrow/><mml:mo>&#x02217;</mml:mo></mml:mrow></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq41.gif"/></alternatives></inline-formula>
<italic>p</italic>-value &#x0003c; 0.001, <inline-formula id="IEq42"><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{\text {a}}$$\end{document}</tex-math><mml:math id="M84"><mml:mmultiscripts><mml:mrow/><mml:mrow/><mml:mtext>a</mml:mtext></mml:mmultiscripts></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq42.gif"/></alternatives></inline-formula>Fisher exact test IO: Immunotherapy, IO &#x00026;CT: IO &#x00026; Chemotherapy, IO&#x00026;RT: IO &#x00026; Radiotherapy, IO&#x00026;TT: IO &#x00026; Targeted therapy</p></table-wrap-foot></table-wrap></p><p id="Par25">Demographic, clinical and PBD data collected from training and testing sets and used as input in models are described in Table <xref rid="MOESM1" ref-type="media">S1</xref>. Patients in Center3 had significantly less patients with a ECOG-PS score of 0, only 9 (12%), in contrast to the 76 (36%) seen in Center1 and 42 (31%) in Center2. Center3 had significantly more patients with &#x0003c;&#x000a0;1% PDL-1 positive tumor cells, 62 patients (83%), in contrast to the 50 (24%) and 28 (20%) patients observed in Center1 and Center2, respectively. Additional differences were observed in sex, BMI, smoking status, steroid and proton pump inhibitor (PPI) use, histology, driven mutations, number of distant metastases and metastatic sites, and collected PBD levels.</p></sec><sec id="Sec14"><title>Baseline and temporal patterns of progression</title><p id="Par26">Out of 14 monitored PBD biomarkers and 20 baseline variables, 65 features were generated after converting categorical variables into dummy. For multivariate models, 25 (Table S4) and 26 (Table S6) variables were selected for baseline (MV-BM) and delta (MV-DM) models, respectively. 9 features were selected for the longitudinal approach (MV-JM), as detailed in Table S8. Schoenfeld residual test was significant for MV-BM (<inline-formula id="IEq43"><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.001$$\end{document}</tex-math><mml:math id="M86"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq43.gif"/></alternatives></inline-formula>) and MV-DM (<inline-formula id="IEq44"><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.05$$\end{document}</tex-math><mml:math id="M88"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq44.gif"/></alternatives></inline-formula>), indicating that the PH assumption is not met for these models and associated with coefficient bias. For both MV-JM and NLR-JM final models, the Gelman&#x02013;Rubin diagnostic <inline-formula id="IEq45"><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hat{\hbox {R}}$$\end{document}</tex-math><mml:math id="M90"><mml:mover accent="true"><mml:mtext>R</mml:mtext><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq45.gif"/></alternatives></inline-formula> associated with each parameter estimate was equal to 1.00 or less than 1.05, indicating good convergence of the MCMC algorithm. The impact on progression of selected features in each model, expressed as HRs, is shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, including NLR-based models with baseline (NLR-BM), delta (NLR-DM) and longitudinal (NLR-JM) data.<fig id="Fig2"><label>Fig. 2</label><caption><p>In A, the logarithm of <inline-formula id="IEq46"><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {norm}}$$\end{document}</tex-math><mml:math id="M92"><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>norm</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq46.gif"/></alternatives></inline-formula> computed by each model, in the normalized scale, is displayed. HRs represent the relative risk of progression, taking into account the other features also included in each model. ln(<inline-formula id="IEq47"><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {norm}})&#x0003e;0$$\end{document}</tex-math><mml:math id="M94"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>norm</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x0003e;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq47.gif"/></alternatives></inline-formula> indicates an increased risk of progression at 6 months (red) and ln(<inline-formula id="IEq48"><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {norm}})&#x0003c;0$$\end{document}</tex-math><mml:math id="M96"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>norm</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x0003c;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq48.gif"/></alternatives></inline-formula> shows a lower progression risk (blue). Feature selection was performed independently for each model with excluded features shown in white (ln(<inline-formula id="IEq49"><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {norm}})=0$$\end{document}</tex-math><mml:math id="M98"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>norm</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq49.gif"/></alternatives></inline-formula>). The models differ by the selection of variables used (multivariate: MV, univariate: NLR) and the use of monitored variables (baseline: BM, delta: DM, longitudinal: JM). <inline-formula id="IEq50"><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {norm}}$$\end{document}</tex-math><mml:math id="M100"><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>norm</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq50.gif"/></alternatives></inline-formula> for MV-JM and NLR-JM models are associated with the survival submodel of the longitudinal model, and monitored features were further used in the longitudinal submodel for making final predictions. In B, AUC and Youden index (J) results in training set (Center1) and in two independent testing sets (Center2 and Center3) when predicting progression at 6, 12 and 24 months. Standard deviations are shown as error bars. It can be noted that MV-BM and MV-DM performance dramatically drops from training to testing results, showing overfitting</p></caption><graphic xlink:href="262_2025_3966_Fig2_HTML" id="MO2"/></fig></p><p id="Par27">Variables in the multivariate and longitudinal MV-JM model take into account the patient&#x02019;s general condition (ECOG-PS, diabetes type I), tumor progression (CNS metastasis), the immune response triggered (pneumonitis, colitis and dermatitis), and the systemic inflammatory state of cancer (LDH, LT and PLR). Significant differences were found between the training and testing sets for ECOG-PS and baseline LDH (see Table S3). Compared to MV-JM, the multivariate baseline and delta MV-BM and MV-DM models included more features related to metastasis location: liver, kidney, bone, nodal, lung and other. The multivariate and baseline MV-BM model also included information about driver mutations (EGFR, ROS1) and medication (steroids, PPI), together with characteristics related to smoking status, number of metastatic sites, irAEs, ALB, Hb and ALI. The multivariate and delta MV-DM model additionally considered features related to biomarker expression (PD-L1) and tumor histology (adenocarcinoma), in addition to other information about COPD, smoking status, number of metastatic locations, irAEs, <inline-formula id="IEq51"><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta$$\end{document}</tex-math><mml:math id="M102"><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq51.gif"/></alternatives></inline-formula>ALB, <inline-formula id="IEq52"><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta$$\end{document}</tex-math><mml:math id="M104"><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq52.gif"/></alternatives></inline-formula>NLR, <inline-formula id="IEq53"><alternatives><tex-math id="M105">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta$$\end{document}</tex-math><mml:math id="M106"><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq53.gif"/></alternatives></inline-formula>MLR, <inline-formula id="IEq54"><alternatives><tex-math id="M107">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta$$\end{document}</tex-math><mml:math id="M108"><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq54.gif"/></alternatives></inline-formula>PNI, and <inline-formula id="IEq55"><alternatives><tex-math id="M109">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta$$\end{document}</tex-math><mml:math id="M110"><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq55.gif"/></alternatives></inline-formula>ALI.</p><p id="Par28">MV-JM modeled trajectories of temporal variables are represented in Fig. S2 along with the trajectories from several responders (red) vs non-responder cases (blue) from the testing sets. The intercepts correspond to the reference value for high or low probability of progression at baseline. For the MV-JM model, a rapid increase in LDH, a rapid decrease in LT, and a very slow decrease or change in PLR resulted in higher probability of progression. Similarly, in the NLR-JM model, a very slow decrease or no change in NLR also predicts a higher chance of progression. Observing the trajectories of the three variables for the responders vs non-responders patients we can verify that they match the temporal patterns defined by the model. Model features, HRs with their p values and RSE values are shown in Tables S4&#x02013;S9. Most predictors in all 6 models (MV-BM, NLR-BM, MV-DM, NLR-DM, MV-JM and NLR-JM) have low RSEs (&#x0003c;&#x000a0;50%), suggesting good parameter identifiability and indicating that the primary insights from the models are robust.</p></sec><sec id="Sec15"><title>Model performance among different progression times and patient groups</title><p id="Par29">Considering the computed probabilities of progression at 6, 12, and 24 months, the multivariate and longitudinal MV-JM model demonstrated a significant performance improvement over the multivariate and NLR-based baseline and delta models in both Center2 and Center3 clinical centers (testing sets): <inline-formula id="IEq56"><alternatives><tex-math id="M111">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {Center2}}_{6\text {mo}}$$\end{document}</tex-math><mml:math id="M112"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>6</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>Center2</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq56.gif"/></alternatives></inline-formula> = 0.870 (0.031), <inline-formula id="IEq57"><alternatives><tex-math id="M113">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {Center2}}_{12\text {mo}}$$\end{document}</tex-math><mml:math id="M114"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>12</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>Center2</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq57.gif"/></alternatives></inline-formula> = 0.804 (0.040), <inline-formula id="IEq58"><alternatives><tex-math id="M115">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {Center2}}_{24\text {mo}}$$\end{document}</tex-math><mml:math id="M116"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>24</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>Center2</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq58.gif"/></alternatives></inline-formula> = 0.827 (0.039) and <inline-formula id="IEq59"><alternatives><tex-math id="M117">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {Center3}}_{6 \text {mo}}$$\end{document}</tex-math><mml:math id="M118"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>6</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>Center3</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq59.gif"/></alternatives></inline-formula> = 0.824 (0.060), <inline-formula id="IEq60"><alternatives><tex-math id="M119">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {Center3}}_{12 \text {mo}}$$\end{document}</tex-math><mml:math id="M120"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>12</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>Center3</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq60.gif"/></alternatives></inline-formula> = 0.822 (0.064), <inline-formula id="IEq61"><alternatives><tex-math id="M121">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {Center3}}_{24 \text {mo}}$$\end{document}</tex-math><mml:math id="M122"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>24</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>Center3</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq61.gif"/></alternatives></inline-formula> = 0.667 (0.206). If combined all three clinical centers: <inline-formula id="IEq62"><alternatives><tex-math id="M123">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {All}}_{6 \text {mo}}$$\end{document}</tex-math><mml:math id="M124"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>6</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>All</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq62.gif"/></alternatives></inline-formula> = 0.832 (0.021), <inline-formula id="IEq63"><alternatives><tex-math id="M125">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {All}}_{12 \text {mo}}$$\end{document}</tex-math><mml:math id="M126"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>12</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>All</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq63.gif"/></alternatives></inline-formula> = 0.787 (0.025), <inline-formula id="IEq64"><alternatives><tex-math id="M127">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {AUC}^{\text {All}}_{24 \text {mo}}$$\end{document}</tex-math><mml:math id="M128"><mml:msubsup><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mn>24</mml:mn><mml:mtext>mo</mml:mtext></mml:mrow><mml:mtext>All</mml:mtext></mml:msubsup></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq64.gif"/></alternatives></inline-formula> = 0.792 (0.034). The multivariate baseline and delta MV-BM and MV-DM models showed overfitting in Center1, reflected in the lack of generalization when faced with new cases in Center2 and Center3 (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). In Table S10, 10-fold IC analysis demonstrates that the multivariate approach consistently outperforms NLR across all three modeling frameworks (BM, DM, JM), as reflected by lower information criterion values.</p><p id="Par30">We investigated potential differences in the AUCs of the multivariate and NLR-based longitudinal models (MV-JM and NLR-JM) for both Center2 and Center3 clinical centers; both longitudinal models obtained higher AUC values (<inline-formula id="IEq65"><alternatives><tex-math id="M129">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;$$\end{document}</tex-math><mml:math id="M130"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq65.gif"/></alternatives></inline-formula> 0.05) and lower standard deviations at 6, 12 and 24 months compared to baseline and delta models in these two hospitals. No significant differences were observed between both longitudinal models MV-JM and NLR-JM. AUC at 24 months was slightly lower in Center3, what could be explained by differences in the mean progression-free survival time in this population (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>). A summary with AUC, sensitivity and specificity of the MV and NLR models is shown in Tables <xref rid="MOESM1" ref-type="media">S11</xref> and <xref rid="MOESM1" ref-type="media">S12</xref>, respectively.</p><p id="Par31">When the population was categorized according to the probability of progression after 6 months according to the threshold computed in Center1 (see Figures <xref rid="MOESM1" ref-type="media">S3</xref>&#x02013;<xref rid="MOESM1" ref-type="media">S5</xref>), a low sensitivity or specificity was observed in the multivariate baseline and delta models, and NLR-based baseline, delta and longitudinal models, reflected in poor <italic>J</italic> values (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B and supplementary materials Tables <xref rid="MOESM1" ref-type="media">S11</xref> and <xref rid="MOESM1" ref-type="media">S12</xref>). In this sense, the multivariate and longitudinal MV-JM model achieved significantly more balanced sensitivity and specificity in Center2 and Center3 clinical centers, with significantly higher <italic>J</italic> values. Despite the low specificity observed for the longitudinal NLR-JM model, Kaplan&#x02013;Meier PFS and OS curves were significantly different for responder and non-responder groups predicted. A higher significancy and narrower confidence interval bands for the multivariate and longitudinal MV-JM model were shown, demonstrating that this model may be a better predictor of progression to immunotherapy in advanced NSCLC. Survival predictions generated by MV-JM align more closely with observed Kaplan&#x02013;Meier estimates compared to those from NLR-JM. In the case of the Center3 cohort, the simulated curves from MV-JM were less accurate, likely due to limited data availability and variations in treatment protocols (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and Figure S6).<fig id="Fig3"><label>Fig. 3</label><caption><p>PFS KM curves estimated by the longitudinal and multivariate MV-JM model and the longitudinal and univariate NLR-JM model predicting responder (blue) or non-responders (red) in Center2 and Center3 testing sets. Simulated survival curves are shown in gray, with solid lines representing responders and dashed lines representing the non-responder group. Plotted groups were generated by the corresponding cutoff value for each model, computed in the training set and applied to both testing sets. Log-rank test p-value for KM curves is displayed</p></caption><graphic xlink:href="262_2025_3966_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>PFS and OS KM curves estimated by the multivariate longitudinal model (MV-JM) in the resultant population from merging the two testing sets, Center2 and Center3. Responders (blue) and non-responders (red) were defined by the cutoff value computed in the training set. Each row represents: (1) KM of merged testing sets, (2) monotherapy (solid line) vs. combined immunotherapy (dashed line) groups and (3) first (solid line) vs. subsequent lines (dashed line) of immunotherapy. Log-rank test p values are shown per group</p></caption><graphic xlink:href="262_2025_3966_Fig4_HTML" id="MO4"/></fig></p><p id="Par32">PFS and OS Kaplan&#x02013;Meier curves of testing patients predicted as responders and non-responders were also significantly different independently of the line of treatment, first vs subsequent lines, and the treatment option, monotherapy vs other (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). No significant differences were found with respect to sex. Additionally, patients predicted as responders by MV-JM account for 85% and 92% of patients with an observed complete or partial response in Center2 and Center3, respectively.</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par33">For an automatic prediction of NSCLC response to treatment, clinical information is often used as a minor aid and the value it can have on its own over time has not yet been exploited. Our previous work has focused on the utilization of clinical information from early treatment for monitoring response, but as part of a multimodal deep-learning-based approach leveraging non-censored RWD [<xref ref-type="bibr" rid="CR33">33</xref>]. The incorporation of censored RWD easily collected from EHRs would simplify patient eligibility and inclusion requirements would be less restrictive, bringing the algorithms closer to clinical reality. The majority of research on longitudinal RWD and JM, which allows the use of censored information, has focused on pharmacokinetics [<xref ref-type="bibr" rid="CR21">21</xref>]. However, some studies have successfully used RWD from medical records to aid in the stratification of cancer patients and there is a growing acknowledgment of the potential value of RWD in the context of lung cancer research [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par34">This study employed demographic, epidemiological, and longitudinal PBD from three clinical centers to predict the progression of patients with advanced NSCLC to immunotherapy at three distinct time points: 6, 12, and 24 months. Results from different input features, PBD sample time points, and underlying model frameworks were compared to determine which approach achieved the best performance in predicting progression to immunotherapy in a RWD setting. Previous work on JM in NSCLC treated with immunotherapy has been conducted within the context of controlled clinical trials [<xref ref-type="bibr" rid="CR22">22</xref>]. Our study represents the first application of JM using RWD from advanced NSCLC patients to predict progression to immunotherapy.</p><p id="Par35">Our results suggest that combining a stepwise selection of variables, longitudinal information and a Bayesian-based framework (MV-JM) achieved a better performance in two independent test set in terms of AUC, youden index J. Despite the higher complexity of MV-JM, 10-fold IC was lower than NLR-JM and Cox-based models. This suggests that the inclusion of additional variables and longitudinal information improves the model&#x02019;s ability to explain the variability in the data more effectively. This model was also able to significantly stratify patients into high and low risk of progression (<inline-formula id="IEq66"><alternatives><tex-math id="M131">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.001$$\end{document}</tex-math><mml:math id="M132"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq66.gif"/></alternatives></inline-formula>) and death (<inline-formula id="IEq67"><alternatives><tex-math id="M133">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p&#x0003c;0.001$$\end{document}</tex-math><mml:math id="M134"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq67.gif"/></alternatives></inline-formula>) according to the Kaplan&#x02013;Meier curves and the long-rank test. In MV-JM, variables selected were CNS metastasis, pneumonitis, colitis, diabetes type I, LDH, LT and PLR.</p><p id="Par36">CNS metastasis (<inline-formula id="IEq68"><alternatives><tex-math id="M135">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=1.47, p&#x0003c;0.05$$\end{document}</tex-math><mml:math id="M136"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>1.47</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq68.gif"/></alternatives></inline-formula>) was related to a higher progression risk and is considered a protective type of metastasis for tumor cells, given the ability of the blood&#x02013;brain barrier to impair immune activity [<xref ref-type="bibr" rid="CR35">35</xref>]. Pneumonitis (<inline-formula id="IEq69"><alternatives><tex-math id="M137">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=2.03, p&#x0003c;0.05$$\end{document}</tex-math><mml:math id="M138"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>2.03</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq69.gif"/></alternatives></inline-formula>), linked to a higher probability of progression, is considered an irAE that could aggravate pulmonary functions already compromised by cancer, while dermatitis (<inline-formula id="IEq70"><alternatives><tex-math id="M139">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=0.62, p=0.81$$\end{document}</tex-math><mml:math id="M140"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>0.62</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.81</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq70.gif"/></alternatives></inline-formula>) and colitis (<inline-formula id="IEq71"><alternatives><tex-math id="M141">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=0.13, p&#x0003c;0.05$$\end{document}</tex-math><mml:math id="M142"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>0.13</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq71.gif"/></alternatives></inline-formula>) could be related to an increased response and a good prognosis [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. ECOG-PS (<inline-formula id="IEq72"><alternatives><tex-math id="M143">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=2.82, p&#x0003c;0.001$$\end{document}</tex-math><mml:math id="M144"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>2.82</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq72.gif"/></alternatives></inline-formula>), associated with a higher progression risk, is related to a poor immune response [<xref ref-type="bibr" rid="CR38">38</xref>]. Further research is required regarding to diabetes type I, associated with a better prognosis in MV-JM (<inline-formula id="IEq73"><alternatives><tex-math id="M145">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=0.52, p=0.22$$\end{document}</tex-math><mml:math id="M146"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>0.52</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.22</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq73.gif"/></alternatives></inline-formula>), since previous research focuses on diabetic type II [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par37">LDH (<inline-formula id="IEq74"><alternatives><tex-math id="M147">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=1.27, p&#x0003c;0.001$$\end{document}</tex-math><mml:math id="M148"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>1.27</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq74.gif"/></alternatives></inline-formula>) was associated with a higher risk of progression, as a key enzyme in glycolytic metabolism in tumor cells, related to tumor evasion, metastasis, angiogenesis, and immune escape [<xref ref-type="bibr" rid="CR40">40</xref>]. Lymphopenia confers poorer survival in immunotherapy-treated patients and an increase in LT levels post-treatment (<inline-formula id="IEq75"><alternatives><tex-math id="M149">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=0.97, p=0.91$$\end{document}</tex-math><mml:math id="M150"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>0.97</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.91</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq75.gif"/></alternatives></inline-formula>) have been associated with higher OS and PFS. On the contrary, platelets have been identified to express immunosuppressors associated with T cell dysfunction and PLR with immune-response impairment (<inline-formula id="IEq76"><alternatives><tex-math id="M151">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {HR}_{\text {orig}}=1.23, p=0.07$$\end{document}</tex-math><mml:math id="M152"><mml:mrow><mml:msub><mml:mtext>HR</mml:mtext><mml:mtext>orig</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>1.23</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.07</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq76.gif"/></alternatives></inline-formula>) [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par38">The dynamics of LDH, LT and PLR during early treatment may also play an important role in patient response to immunotherapy in line with our results. According to the JM model output, intercept and slope estimated in the longitudinal submodel we could identify the expected trajectory of these features. Deviations from this linear trajectory are associated with changes in the predicted progression risk, modifying the HR originally estimated in the survival submodel (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A) according to the dynamics of the monitored feature. MV-JM results suggest that a fast increasing LDH value, a fast decreasing LT value, and a slow decreasing PLR value from the predicted baseline values (LDH = 329.94 U/L, LT = 1543.98 /<inline-formula id="IEq77"><alternatives><tex-math id="M153">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mu$$\end{document}</tex-math><mml:math id="M154"><mml:mi>&#x003bc;</mml:mi></mml:math><inline-graphic xlink:href="262_2025_3966_Article_IEq77.gif"/></alternatives></inline-formula>L, PLR = 6.34) are related to a higher probability of progression. LDH has never been analyzed longitudinally for predicting immunotherapy response, in some cases paired with some temporal information, but always used at baseline [<xref ref-type="bibr" rid="CR45">45</xref>]. On the other hand, a longitudinal NLR-based model (NLR-JM) predicts a higher probability of progression if a slow decreasing NLR value is observed from the predicted baseline value (NLR = 6.34).</p><p id="Par39">Some limitations of our study comprise the retrospective nature of data, population heterogeneity, availability of longitudinal patient information, and generally short progression-free time in cohorts. Treatment heterogeneity related to immunotherapy regimes, number of lines or PDL-1-based selection criteria across centers may have influenced model performance. Particularly for Center3 MV-JM exhibited lower long-term predictive accuracy as reflected in both lower AUC values and simulated survival curves. Evolving clinical guidelines contributed to these differences. During the period when Center3 cases were treated, patients with low PD-L1 expression could receive immunotherapy as monotherapy. In contrast, current guidelines suggest combining chemotherapy with immunotherapy for such patients, highlighting the impact of temporal changes in clinical practice on the study outcomes. Despite these challenges, JM models outperformed the CPH models, likely due to their ability to account for between-subject variability through the incorporation of random effects in the longitudinal submodel. Using two independent test centers also demonstrated the superior generalizability and robustness of MV-JM. In future research we plan to explore advanced regularization methods, such as Lasso or elastic net, to address the overfitting observed in BM and DM models, as well as the integration of baseline and delta information into a single unified model. Additionally, we may include more patients with prolonged responses to predict long-term response [<xref ref-type="bibr" rid="CR46">46</xref>] and the integration of variables studied with other relevant molecular parameters that can be monitored, such as circulating tumor DNA (ctDNA).</p><p id="Par40">We have demonstrated the prognostic prediction value of monitoring peripheral blood variables and developed a decision support tool with easily collected RWD available in hospitals. Our results demonstrate that the temporal component in the model may account for changes related to the dynamics of the tumor microenvironment in three heterogenous cohorts, offsetting the lack of robustness and reliability that baseline and delta features provided on their own. Combining different variables may also lead to a more comprehensive assessment of tumor response and effective monitoring of the effects of cancer treatment compared to the use of a single biomarker such as NLR. A Bayesian joint model allows a much simpler and intuitive assessment of variable relevance for prediction compared to multimodal or deep learning approaches, which further aids the physician&#x02019;s decision-making and accounts for the patient&#x02019;s clinical and immunological context.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="262_2025_3966_MOESM1_ESM.pdf"><caption><p>Supplementary file 1 (pdf 4560 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors acknowledge the support of Ministerio de Ciencia e Innovaci&#x000f3;n, Agencia Estatal de Investigaci&#x000f3;n, under grants PDC2022-133865-I00 and PID2022-141493OB-I00 (10.13039/501100011033/MCIN/AEI/ERDF, UE), co-financed by European Regional Development Fund (ERDF), &#x02018;A way of making Europe&#x02019;. Additionally, this work has been developed with the financial support of Instituto de Salud Carlos III (ISCIII) project INGENIO (PMP21/00107) and the Next Generation EU funds. This work was partially funded by the Leonardo grant to researchers and cultural creators 2019 from Fundaci&#x000f3;n BBVA. BF was supported by an FPI grant from Spain&#x02019;s Ministry of Education.&#x000a0;The authors further&#x000a0;acknowledge partial funding from the MAGERIT-CM project (TEC-2024/COM-44), supported by the Research and Development in Technologies&#x000a0;program&#x000a0;of the Comunidad de Madrid.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Experimental design was conducted by ADRG, BF, and MJLC. Data collection and curation were performed by all authors. Data analysis and interpretation were carried out by ADRG, BF, and MJLC. Clinical assessment&#x000a0;was performed by JRP, AVL, JZ, GPB, LMS, LPA, IGB, and MDG. MJLC supervised the project and managed resource acquisition. The manuscript was written by ADRG, BF, and MJLC. All authors reviewed and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data used in this study are available upon reasonable request from the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par41">The authors ADRG, BF, JRP, and MJLC did not report any potential Conflict of interest.&#x000a0;AVL declares contracts with AstraZeneca, speaker roles for Health in code, and participation in meetings with AstraZeneca, BMS, and Roche. JZ has served as a consultant for Sanofi, AstraZeneca, BMS, Roche, Pfizer, Novartis, and Guardant Health. He reports speakers&#x02019; honoraria from Janssen, Amgen, Sanofi, Takeda, BMS, Pfizer, Roche, Astra Zeneca, Diagnostica Longwood, and NanoString. He reports travel honoraria from Sanofi, Takeda, BMS, Pfizer, Roche, Astra Zeneca, and NanoString. He has received research support/funds from BMS, Astra Zeneca, and Roche. GPB declares grants from GSK, Chiesi, and Menarini, none of them related to the subject of the paper. LMS reports a role as scientific advisor for Sabartech, Serum, Astra Zeneca, Roche, MSD, and Median technologies, and paid honoraria as a speaker from Astra Zeneca, GSK, Roche, Menarini, and Chiesi. LPA declares grants/contracts from MSD, AstraZeneca, Pfizer, and BMS; consulting fees from Eli Lilly, MSD, Roche, Pharmamar, Merck, AstraZeneca, Novartis, Servier, Amgen, Pfizer, Sanofi, Bayer, BMS, Mirati, GSK, Janssen, Takeda, and Daiichi Sankyo; and payment/honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Janssen, Merck, and Mirati. IGB declares advisory board/speaker roles for Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Roche, Johnson &#x00026; Johnson, MSD, Pfizer, Regeneron, Sanofi, and Takeda. MDG declares consulting/advisory roles for AstraZeneca, Boehringer Ingelheim, Janssen, MSD, Pfizer, Roche, Sanofi, and Takeda; and speaker roles for AstraZeneca, BMS, MSD, Pfizer, Roche, and Takeda.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name></person-group><article-title>Cancer statistics</article-title><source>CA Cancer J Clin</source><year>2020</year><volume>70</volume><issue>1</issue><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21590</pub-id><pub-id pub-id-type="pmid">31912902</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Siegel RL, Miller KD (2020) Cancer statistics. CA Cancer J Clin 70(1):7&#x02013;30. 10.3322/caac.21590<pub-id pub-id-type="pmid">31912902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Vicente</surname><given-names>D</given-names></name><name><surname>Tafreshi</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>A</given-names></name><name><surname>Soto Parra</surname><given-names>H</given-names></name><name><surname>Mazi&#x000e8;res</surname><given-names>J</given-names></name></person-group><article-title>A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407</article-title><source>J Thorac Oncol</source><year>2020</year><volume>15</volume><issue>10</issue><fpage>1657</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.06.015</pub-id><pub-id pub-id-type="pmid">32599071</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazi&#x000e8;res J (2020) A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 15(10):1657&#x02013;1669. 10.1016/j.jtho.2020.06.015<pub-id pub-id-type="pmid">32599071</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>SC</given-names></name><name><surname>Duffy</surname><given-names>CR</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>Fundamental mechanisms of immune checkpoint blockade therapy</article-title><source>Cancer Discov</source><year>2018</year><volume>8</volume><issue>9</issue><fpage>1069</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0367</pub-id><pub-id pub-id-type="pmid">30115704</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069&#x02013;1086. 10.1158/2159-8290.CD-18-0367<pub-id pub-id-type="pmid">30115704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Raychaudhuri</surname><given-names>D</given-names></name><name><surname>Siddiqui</surname><given-names>BA</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Nagarajan</surname><given-names>A</given-names></name></person-group><article-title>Immune checkpoint therapy-current perspectives and future directions</article-title><source>Cell</source><year>2023</year><volume>186</volume><issue>8</issue><fpage>1652</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.03.006</pub-id><pub-id pub-id-type="pmid">37059068</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652&#x02013;1669. 10.1016/j.cell.2023.03.006<pub-id pub-id-type="pmid">37059068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>J</given-names></name><name><surname>De</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Villaflor</surname><given-names>V</given-names></name></person-group><article-title>Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors</article-title><source>Cancer Immunol Immunother</source><year>2024</year><volume>73</volume><issue>11</issue><fpage>234</fpage><pub-id pub-id-type="doi">10.1007/s00262-024-03825-z</pub-id><pub-id pub-id-type="pmid">39271499</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Malhotra J, De S, Nguyen K, Lee P, Villaflor V (2024) Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors. Cancer Immunol Immunother 73(11):234. 10.1007/s00262-024-03825-z<pub-id pub-id-type="pmid">39271499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Vasan</surname><given-names>N</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name></person-group><article-title>A view on drug resistance in cancer</article-title><source>Nature</source><year>2019</year><volume>575</volume><issue>7782</issue><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1730-1</pub-id><pub-id pub-id-type="pmid">31723286</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Vasan N, Baselga J, Hyman DM (2019) A view on drug resistance in cancer. Nature 575(7782):299&#x02013;309. 10.1038/s41586-019-1730-1<pub-id pub-id-type="pmid">31723286</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Copley</surname><given-names>SJ</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Logan</surname><given-names>A</given-names></name><name><surname>Viola</surname><given-names>P</given-names></name></person-group><article-title>A novel radiogenomics biomarker for predicting treatment response and pneumotoxicity from programmed cell death protein or Ligand-1 inhibition immunotherapy in NSCLC</article-title><source>J Thorac Oncol</source><year>2023</year><volume>18</volume><issue>6</issue><fpage>718</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2023.01.089</pub-id><pub-id pub-id-type="pmid">36773776</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chen M, Lu H, Copley SJ, Han Y, Logan A, Viola P (2023) A novel radiogenomics biomarker for predicting treatment response and pneumotoxicity from programmed cell death protein or Ligand-1 inhibition immunotherapy in NSCLC. J Thorac Oncol 18(6):718&#x02013;730. 10.1016/j.jtho.2023.01.089<pub-id pub-id-type="pmid">36773776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>KM</given-names></name><name><surname>Khosravi</surname><given-names>P</given-names></name><name><surname>Vanguri</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>SP</given-names></name></person-group><article-title>Harnessing multimodal data integration to advance precision oncology</article-title><source>Nat Rev Cancer</source><year>2022</year><volume>22</volume><issue>2</issue><fpage>114</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00408-3</pub-id><pub-id pub-id-type="pmid">34663944</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Boehm KM, Khosravi P, Vanguri R, Gao J, Shah SP (2022) Harnessing multimodal data integration to advance precision oncology. Nat Rev Cancer 22(2):114&#x02013;126. 10.1038/s41568-021-00408-3<pub-id pub-id-type="pmid">34663944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Khozin</surname><given-names>S</given-names></name><name><surname>Blumenthal</surname><given-names>GM</given-names></name><name><surname>Pazdur</surname><given-names>R</given-names></name></person-group><article-title>Real-world data for clinical evidence generation in oncology</article-title><source>J Natl Cancer Inst</source><year>2017</year><volume>109</volume><issue>11</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1093/jnci/djx187</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Khozin S, Blumenthal GM, Pazdur R (2017) Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst 109(11):1. 10.1093/jnci/djx187</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Valero</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Hoen</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>DW</given-names></name><name><surname>Adusumilli</surname><given-names>PS</given-names></name></person-group><article-title>Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>729</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-20935-9</pub-id><pub-id pub-id-type="pmid">33526794</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS (2021) Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun 12(1):729. 10.1038/s41467-021-20935-9<pub-id pub-id-type="pmid">33526794</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Kiriu</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Nagano</surname><given-names>T</given-names></name><name><surname>Hazama</surname><given-names>D</given-names></name><name><surname>Sekiya</surname><given-names>R</given-names></name><name><surname>Katsurada</surname><given-names>M</given-names></name></person-group><article-title>The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><issue>2</issue><fpage>0193018</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0193018</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M (2018) The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE 13(2):0193018. 10.1371/journal.pone.0193018</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name></person-group><article-title>The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study</article-title><source>Cancer Immunol Immunother CII</source><year>2023</year><volume>72</volume><issue>3</issue><fpage>783</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1007/s00262-022-03262-w</pub-id><pub-id pub-id-type="pmid">36056951</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Li C, Wu J, Jiang L, Zhang L, Huang J, Tian Y (2023) The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study. Cancer Immunol Immunother CII 72(3):783&#x02013;794. 10.1007/s00262-022-03262-w<pub-id pub-id-type="pmid">36056951</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Mountzios</surname><given-names>G</given-names></name><name><surname>Samantas</surname><given-names>E</given-names></name><name><surname>Senghas</surname><given-names>K</given-names></name><name><surname>Zervas</surname><given-names>E</given-names></name><name><surname>Krisam</surname><given-names>J</given-names></name><name><surname>Samitas</surname><given-names>K</given-names></name></person-group><article-title>Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer</article-title><source>ESMO Open</source><year>2021</year><volume>6</volume><issue>5</issue><fpage>100254</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2021.100254</pub-id><pub-id pub-id-type="pmid">34481329</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K (2021) Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open 6(5):100254. 10.1016/j.esmoop.2021.100254<pub-id pub-id-type="pmid">34481329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Shoji</surname><given-names>F</given-names></name><name><surname>Takeoka</surname><given-names>H</given-names></name><name><surname>Kozuma</surname><given-names>Y</given-names></name><name><surname>Toyokawa</surname><given-names>G</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Ichiki</surname><given-names>M</given-names></name><name><surname>Takeo</surname><given-names>S</given-names></name></person-group><article-title>Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors</article-title><source>Lung Cancer</source><year>2019</year><volume>136</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.08.006</pub-id><pub-id pub-id-type="pmid">31437663</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Shoji F, Takeoka H, Kozuma Y, Toyokawa G, Yamazaki K, Ichiki M, Takeo S (2019) Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer 136:45&#x02013;51. 10.1016/j.lungcan.2019.08.006<pub-id pub-id-type="pmid">31437663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>Havel</surname><given-names>JJ</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Desrichard</surname><given-names>A</given-names></name><name><surname>Urba</surname><given-names>WJ</given-names></name><name><surname>Sims</surname><given-names>JS</given-names></name></person-group><article-title>Tumor and microenvironment evolution during immunotherapy with nivolumab</article-title><source>Cell</source><year>2017</year><volume>171</volume><issue>4</issue><fpage>934</fpage><lpage>94915</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.028</pub-id><pub-id pub-id-type="pmid">29033130</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS (2017) Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171(4):934&#x02013;94915. 10.1016/j.cell.2017.09.028<pub-id pub-id-type="pmid">29033130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Rizopoulos</surname><given-names>D</given-names></name></person-group><article-title>JM: an R package for the joint modelling of longitudinal and time-to-event data</article-title><source>J Stat Softw</source><year>2010</year><volume>35</volume><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.18637/jss.v035.i09</pub-id><pub-id pub-id-type="pmid">21603108</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Rizopoulos D (2010) JM: an R package for the joint modelling of longitudinal and time-to-event data. J Stat Softw 35:1&#x02013;33. 10.18637/jss.v035.i09<pub-id pub-id-type="pmid">21603108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Mercier</surname><given-names>F</given-names></name><name><surname>Kerioui</surname><given-names>M</given-names></name><name><surname>Desm&#x000e9;e</surname><given-names>S</given-names></name><name><surname>Guedj</surname><given-names>J</given-names></name><name><surname>Krieter</surname><given-names>O</given-names></name><name><surname>Bruno</surname><given-names>R</given-names></name></person-group><article-title>Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2020</year><volume>47</volume><issue>6</issue><fpage>613</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1007/s10928-020-09714-z</pub-id><pub-id pub-id-type="pmid">32865652</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Mercier F, Kerioui M, Desm&#x000e9;e S, Guedj J, Krieter O, Bruno R (2020) Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. J Pharmacokinet Pharmacodyn 47(6):613&#x02013;625. 10.1007/s10928-020-09714-z<pub-id pub-id-type="pmid">32865652</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Riglet</surname><given-names>F</given-names></name><name><surname>Mentre</surname><given-names>F</given-names></name><name><surname>Veyrat-Follet</surname><given-names>C</given-names></name><name><surname>Bertrand</surname><given-names>J</given-names></name></person-group><article-title>Bayesian individual dynamic predictions with uncertainty of longitudinal biomarkers and risks of survival events in a joint modelling framework: a comparison between Stan, Monolix, and NONMEM</article-title><source>AAPS J</source><year>2020</year><volume>22</volume><issue>2</issue><fpage>50</fpage><pub-id pub-id-type="doi">10.1208/s12248-019-0388-9</pub-id><pub-id pub-id-type="pmid">32076894</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Riglet F, Mentre F, Veyrat-Follet C, Bertrand J (2020) Bayesian individual dynamic predictions with uncertainty of longitudinal biomarkers and risks of survival events in a joint modelling framework: a comparison between Stan, Monolix, and NONMEM. AAPS J 22(2):50. 10.1208/s12248-019-0388-9<pub-id pub-id-type="pmid">32076894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Chatfield C (2000) Time-series forecasting. New York. 10.1201/9781420036206</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Alsefri</surname><given-names>M</given-names></name><name><surname>Sudell</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a-Fi&#x000f1;ana</surname><given-names>M</given-names></name><name><surname>Kolamunnage-Dona</surname><given-names>R</given-names></name></person-group><article-title>Bayesian joint modelling of longitudinal and time to event data: a methodological review</article-title><source>BMC Med Res Methodol</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/s12874-020-00976-2</pub-id><pub-id pub-id-type="pmid">32336264</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Alsefri M, Sudell M, Garc&#x000ed;a-Fi&#x000f1;ana M, Kolamunnage-Dona R (2020) Bayesian joint modelling of longitudinal and time to event data: a methodological review. BMC Med Res Methodol 20(1):94. 10.1186/s12874-020-00976-2<pub-id pub-id-type="pmid">32336264</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Kerioui</surname><given-names>M</given-names></name><name><surname>Beaulieu</surname><given-names>M</given-names></name><name><surname>Desm&#x000e9;e</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>J</given-names></name><name><surname>Mercier</surname><given-names>F</given-names></name><name><surname>Jin</surname><given-names>JY</given-names></name></person-group><article-title>Nonlinear multilevel joint model for individual lesion kinetics and survival to characterize intra-individual heterogeneity in patients with advanced cancer</article-title><source>Biometrics</source><year>2023</year><volume>79</volume><issue>4</issue><fpage>3752</fpage><lpage>3763</lpage><pub-id pub-id-type="doi">10.1111/biom.13912</pub-id><pub-id pub-id-type="pmid">37498050</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kerioui M, Beaulieu M, Desm&#x000e9;e S, Bertrand J, Mercier F, Jin JY (2023) Nonlinear multilevel joint model for individual lesion kinetics and survival to characterize intra-individual heterogeneity in patients with advanced cancer. Biometrics 79(4):3752&#x02013;3763. 10.1111/biom.13912<pub-id pub-id-type="pmid">37498050</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Gavrilov</surname><given-names>S</given-names></name><name><surname>Zhudenkov</surname><given-names>K</given-names></name><name><surname>Helmlinger</surname><given-names>G</given-names></name><name><surname>Dunyak</surname><given-names>J</given-names></name><name><surname>Peskov</surname><given-names>K</given-names></name><name><surname>Aksenov</surname><given-names>S</given-names></name></person-group><article-title>Longitudinal tumor size and neutrophil-to-lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced non-small cell lung cancer treated with durvalumab</article-title><source>CPT Pharmacomet Syst Pharmacol</source><year>2021</year><volume>10</volume><issue>1</issue><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/psp4.12578</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Gavrilov S, Zhudenkov K, Helmlinger G, Dunyak J, Peskov K, Aksenov S (2021) Longitudinal tumor size and neutrophil-to-lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced non-small cell lung cancer treated with durvalumab. CPT Pharmacomet Syst Pharmacol 10(1):67&#x02013;74. 10.1002/psp4.12578</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Kundu</surname><given-names>D</given-names></name><name><surname>Sarkar</surname><given-names>P</given-names></name><name><surname>Gogoi</surname><given-names>MP</given-names></name><name><surname>Das</surname><given-names>K</given-names></name></person-group><article-title>A Bayesian joint model for multivariate longitudinal and time-to-event data with application to ALL maintenance studies</article-title><source>J Biopharm Stat</source><year>2024</year><volume>34</volume><issue>1</issue><fpage>37</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1080/10543406.2023.2187413</pub-id><pub-id pub-id-type="pmid">36882959</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kundu D, Sarkar P, Gogoi MP, Das K (2024) A Bayesian joint model for multivariate longitudinal and time-to-event data with application to ALL maintenance studies. J Biopharm Stat 34(1):37&#x02013;54. 10.1080/10543406.2023.2187413<pub-id pub-id-type="pmid">36882959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Alvarez</surname><given-names>A</given-names></name><name><surname>Cubero</surname><given-names>JH</given-names></name><name><surname>Capdevila</surname><given-names>J</given-names></name></person-group><article-title>What is the status of immunotherapy in neuroendocrine neoplasms?</article-title><source>Current Oncol Rep</source><year>2022</year><volume>24</volume><issue>4</issue><fpage>451</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1007/s11912-022-01235-x</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Garcia-Alvarez A, Cubero JH, Capdevila J (2022) What is the status of immunotherapy in neuroendocrine neoplasms? Current Oncol Rep 24(4):451&#x02013;461. 10.1007/s11912-022-01235-x</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname><given-names>SD</given-names></name><name><surname>Tucker</surname><given-names>M</given-names></name><name><surname>Bowser</surname><given-names>B</given-names></name><name><surname>Calkins</surname><given-names>G</given-names></name><name><surname>C-hJ</surname><given-names>Chang</given-names></name><name><surname>Guardino</surname><given-names>E</given-names></name></person-group><article-title>Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer</article-title><source>Adv Ther</source><year>2019</year><volume>36</volume><issue>8</issue><fpage>2122</fpage><lpage>2136</lpage><pub-id pub-id-type="doi">10.1007/s12325-019-00970-1</pub-id><pub-id pub-id-type="pmid">31140124</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Griffith SD, Tucker M, Bowser B, Calkins G, C-hJ Chang, Guardino E (2019) Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer. Adv Ther 36(8):2122&#x02013;2136. 10.1007/s12325-019-00970-1<pub-id pub-id-type="pmid">31140124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Kok</surname><given-names>P-S</given-names></name><name><surname>Cho</surname><given-names>D</given-names></name><name><surname>Yoon</surname><given-names>W-H</given-names></name><name><surname>Ritchie</surname><given-names>G</given-names></name><name><surname>Marschner</surname><given-names>I</given-names></name><name><surname>Lord</surname><given-names>S</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name><name><surname>Simes</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name></person-group><article-title>Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>9</issue><fpage>2011809</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.11809</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Kok P-S, Cho D, Yoon W-H, Ritchie G, Marschner I, Lord S, Friedlander M, Simes J, Lee CK (2020) Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis. JAMA Netw Open 3(9):2011809. 10.1001/jamanetworkopen.2020.11809</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Committee for Medicinal Products for Human Use: Guideline on missing data in confirmatory clinical trials (2010) Scientific guideline EMA/CPMP/EWP/1776/99 Rev. 1, European Medicines Agency</mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Castela Forte</surname><given-names>J</given-names></name><name><surname>Yeshmagambetova</surname><given-names>G</given-names></name><name><surname>Grinten</surname><given-names>ML</given-names></name><name><surname>Hiemstra</surname><given-names>B</given-names></name><name><surname>Kaufmann</surname><given-names>T</given-names></name><name><surname>Eck</surname><given-names>RJ</given-names></name></person-group><article-title>Identifying and characterizing high-risk clusters in a heterogeneous ICU population with deep embedded clustering</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>12109</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-91297-x</pub-id><pub-id pub-id-type="pmid">34103544</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Castela Forte J, Yeshmagambetova G, Grinten ML, Hiemstra B, Kaufmann T, Eck RJ (2021) Identifying and characterizing high-risk clusters in a heterogeneous ICU population with deep embedded clustering. Sci Rep 11:12109. 10.1038/s41598-021-91297-x<pub-id pub-id-type="pmid">34103544</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Correll</surname><given-names>DJ</given-names></name><name><surname>Lechner</surname><given-names>SM</given-names></name><name><surname>Jazic</surname><given-names>I</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Shaw</surname><given-names>D</given-names></name></person-group><article-title>Selective inhibition of NaV1.8 with VX-548 for acute pain</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><issue>5</issue><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2209870</pub-id><pub-id pub-id-type="pmid">37530822</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D (2023) Selective inhibition of NaV1.8 with VX-548 for acute pain. N Engl J Med 389(5):393&#x02013;405. 10.1056/NEJMoa2209870<pub-id pub-id-type="pmid">37530822</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Wyles</surname><given-names>DL</given-names></name><name><surname>Ruane</surname><given-names>PJ</given-names></name><name><surname>Sulkowski</surname><given-names>MS</given-names></name><name><surname>Dieterich</surname><given-names>D</given-names></name><name><surname>Luetkemeyer</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>TR</given-names></name></person-group><article-title>Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>8</issue><fpage>714</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1503153</pub-id><pub-id pub-id-type="pmid">26196502</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR (2015) Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373(8):714&#x02013;725. 10.1056/NEJMoa1503153<pub-id pub-id-type="pmid">26196502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Rizopoulos D (2016) The R package JMbayes for fitting joint models for longitudinal and time-to-event data using MCMC. J Stat Softw 72(7):1&#x02013;46. 10.18637/jss.v072.i07. Section: Articles</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Saha-Chaudhuri</surname><given-names>P</given-names></name><name><surname>Heagerty</surname><given-names>PJ</given-names></name></person-group><article-title>Non-parametric estimation of a time-dependent predictive accuracy curve</article-title><source>Biostatistics</source><year>2013</year><volume>14</volume><issue>1</issue><fpage>42</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxs021</pub-id><pub-id pub-id-type="pmid">22734044</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Saha-Chaudhuri P, Heagerty PJ (2013) Non-parametric estimation of a time-dependent predictive accuracy curve. Biostatistics 14(1):42&#x02013;59. 10.1093/biostatistics/kxs021<pub-id pub-id-type="pmid">22734044</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Farina</surname><given-names>B</given-names></name><name><surname>Ramos-Guerra</surname><given-names>AD</given-names></name><name><surname>Bermejo-Pel&#x000e1;ez</surname><given-names>D</given-names></name><name><surname>Miras</surname><given-names>CP</given-names></name><name><surname>Peral</surname><given-names>AA</given-names></name><name><surname>Madue&#x000f1;o</surname><given-names>GG</given-names></name></person-group><article-title>Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>174</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04004-x</pub-id><pub-id pub-id-type="pmid">36872371</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Farina B, Ramos-Guerra AD, Bermejo-Pel&#x000e1;ez D, Miras CP, Peral AA, Madue&#x000f1;o GG (2023) Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients. J Transl Med 21(1):174. 10.1186/s12967-023-04004-x<pub-id pub-id-type="pmid">36872371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Kokkotou</surname><given-names>E</given-names></name><name><surname>Anagnostakis</surname><given-names>M</given-names></name><name><surname>Evangelou</surname><given-names>G</given-names></name><name><surname>Syrigos</surname><given-names>NK</given-names></name><name><surname>Gkiozos</surname><given-names>I</given-names></name></person-group><article-title>Real-world data and evidence in lung cancer: a review of recent developments</article-title><source>Cancers</source><year>2024</year><volume>16</volume><issue>7</issue><fpage>1414</fpage><pub-id pub-id-type="doi">10.3390/cancers16071414</pub-id><pub-id pub-id-type="pmid">38611092</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kokkotou E, Anagnostakis M, Evangelou G, Syrigos NK, Gkiozos I (2024) Real-world data and evidence in lung cancer: a review of recent developments. Cancers 16(7):1414. 10.3390/cancers16071414<pub-id pub-id-type="pmid">38611092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>C</given-names></name><name><surname>Deangelis</surname><given-names>LM</given-names></name></person-group><article-title>Overview of metastatic disease of the central nervous system</article-title><source>Handb Clin Neurol</source><year>2018</year><volume>149</volume><fpage>3</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-811161-1.00001-3</pub-id><pub-id pub-id-type="pmid">29307359</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Nolan C, Deangelis LM (2018) Overview of metastatic disease of the central nervous system. Handb Clin Neurol 149:3&#x02013;23. 10.1016/B978-0-12-811161-1.00001-3<pub-id pub-id-type="pmid">29307359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>663986</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.663986</pub-id><pub-id pub-id-type="pmid">34122422</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Zhang Q, Tang L, Zhou Y, He W, Li W (2021) Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management. Front Immunol 12:663986. 10.3389/fimmu.2021.663986<pub-id pub-id-type="pmid">34122422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>GE</given-names></name><name><surname>Allen</surname><given-names>IM</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Zubiri</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Mooradian</surname><given-names>MJ</given-names></name></person-group><article-title>Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: a retrospective cohort study</article-title><source>J Am Acad Dermatol</source><year>2020</year><volume>82</volume><issue>3</issue><fpage>743</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2019.07.049</pub-id><pub-id pub-id-type="pmid">31349048</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ (2020) Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: a retrospective cohort study. J Am Acad Dermatol 82(3):743&#x02013;746. 10.1016/j.jaad.2019.07.049<pub-id pub-id-type="pmid">31349048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Friedlaender</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>SV</given-names></name><name><surname>Passaro</surname><given-names>A</given-names></name><name><surname>Metro</surname><given-names>G</given-names></name><name><surname>Banna</surname><given-names>G</given-names></name><name><surname>Addeo</surname><given-names>A</given-names></name></person-group><article-title>The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors</article-title><source>Clin Lung Cancer</source><year>2020</year><volume>21</volume><issue>6</issue><fpage>539</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2020.04.006</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Friedlaender A, Liu SV, Passaro A, Metro G, Banna G, Addeo A (2020) The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors. Clin Lung Cancer 21(6):539&#x02013;543. 10.1016/j.cllc.2020.04.006</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Cortellini</surname><given-names>A</given-names></name><name><surname>D&#x02019;Alessio</surname><given-names>A</given-names></name><name><surname>Cleary</surname><given-names>S</given-names></name><name><surname>Buti</surname><given-names>S</given-names></name><name><surname>Bersanelli</surname><given-names>M</given-names></name><name><surname>Bordi</surname><given-names>P</given-names></name></person-group><article-title>Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer</article-title><source>Clin Cancer Res</source><year>2023</year><volume>29</volume><issue>14</issue><fpage>2714</fpage><lpage>2724</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-3116</pub-id><pub-id pub-id-type="pmid">37125965</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Cortellini A, D&#x02019;Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P (2023) Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer. Clin Cancer Res 29(14):2714&#x02013;2724. 10.1158/1078-0432.CCR-22-3116<pub-id pub-id-type="pmid">37125965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Qiao</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name></person-group><article-title>Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy</article-title><source>Cancer Med</source><year>2018</year><volume>7</volume><issue>12</issue><fpage>6124</fpage><lpage>6136</lpage><pub-id pub-id-type="doi">10.1002/cam4.1820</pub-id><pub-id pub-id-type="pmid">30403008</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y (2018) Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med 7(12):6124&#x02013;6136. 10.1002/cam4.1820<pub-id pub-id-type="pmid">30403008</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Byun</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>MH</given-names></name></person-group><article-title>Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2019</year><volume>105</volume><issue>5</issue><fpage>1065</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2019.08.047</pub-id><pub-id pub-id-type="pmid">31476418</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Cho Y, Park S, Byun HK, Lee CG, Cho J, Hong MH (2019) Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 105(5):1065&#x02013;1073. 10.1016/j.ijrobp.2019.08.047<pub-id pub-id-type="pmid">31476418</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Park</surname><given-names>TY</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Heo</surname><given-names>EY</given-names></name></person-group><article-title>Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>626</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-04630-9</pub-id><pub-id pub-id-type="pmid">35022510</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lee YJ, Park YS, Lee HW, Park TY, Lee JK, Heo EY (2022) Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep 12(1):626. 10.1038/s41598-021-04630-9<pub-id pub-id-type="pmid">35022510</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>T</given-names></name><name><surname>Jain</surname><given-names>K</given-names></name><name><surname>Yarovinsky</surname><given-names>TO</given-names></name><name><surname>Chiorazzi</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Castro</surname><given-names>C</given-names></name></person-group><article-title>Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+T cells</article-title><source>J Exp Med</source><year>2022</year><volume>220</volume><issue>1</issue><fpage>20212218</fpage><pub-id pub-id-type="doi">10.1084/jem.20212218</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Tyagi T, Jain K, Yarovinsky TO, Chiorazzi M, Du J, Castro C (2022) Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+T cells. J Exp Med 220(1):20212218. 10.1084/jem.20212218</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>962173</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.962173</pub-id><pub-id pub-id-type="pmid">36059629</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Zhou K, Cao J, Lin H, Liang L, Shen Z, Wang L (2022) Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. Front Oncol 12:962173. 10.3389/fonc.2022.962173<pub-id pub-id-type="pmid">36059629</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Guida</surname><given-names>M</given-names></name><name><surname>Bartolomeo</surname><given-names>N</given-names></name><name><surname>Quaresmini</surname><given-names>D</given-names></name><name><surname>Quaglino</surname><given-names>P</given-names></name><name><surname>Madonna</surname><given-names>G</given-names></name><name><surname>Pigozzo</surname><given-names>J</given-names></name></person-group><article-title>Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma</article-title><source>J Transl Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s12967-022-03359-x</pub-id><pub-id pub-id-type="pmid">35382857</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Guida M, Bartolomeo N, Quaresmini D, Quaglino P, Madonna G, Pigozzo J (2022) Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. J Transl Med 20(1):159. 10.1186/s12967-022-03359-x<pub-id pub-id-type="pmid">35382857</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Thummalapalli</surname><given-names>R</given-names></name><name><surname>Ricciuti</surname><given-names>B</given-names></name><name><surname>Bandlamudi</surname><given-names>C</given-names></name><name><surname>Muldoon</surname><given-names>D</given-names></name><name><surname>Rizvi</surname><given-names>H</given-names></name><name><surname>Elkrief</surname><given-names>A</given-names></name></person-group><article-title>Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2023</year><volume>29</volume><issue>21</issue><fpage>4408</fpage><lpage>4418</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-1207</pub-id><pub-id pub-id-type="pmid">37432985</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A (2023) Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Clin Cancer Res 29(21):4408&#x02013;4418. 10.1158/1078-0432.CCR-23-1207<pub-id pub-id-type="pmid">37432985</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>